| Dr Brijen L Joshi, MD | |
|
1800 Orleans St, The Johns Hopkins University/the Johns Hopkins Hospital, Baltimore, MD 21287-0010 | |
| (410) 955-5000 | |
| Not Available |
| Full Name | Dr Brijen L Joshi |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 18 Years |
| Location | 1800 Orleans St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114210838 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LC0200X | Anesthesiology - Critical Care Medicine | D81904 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johns Hopkins Bayview Medical Center | Baltimore, MD | Hospital |
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
Anti-osteoporotic medication is not an effective means for preventing hip fractures among the elderly, concludes a study recently published in the BMJ. According to Professor Teppo Järvinen from the University of Helsinki, who heads the research group, the prevalent assumption that brittle bones cause hip fractures is fundamentally flawed.
While the HIV prevalence in China remains low, the situation in several provinces affected by drug trafficking and illegal blood donations is serious, senior HIV/AIDS control officials said on Saturday, Xinhua/China Daily reports.
Inex Pharmaceuticals announced today that United States Food and Drug Administration (FDA) provided an action letter detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval regulations based on the phase 2 clinical trial data submitted.
More than one in ten cancer patients do not die from their cancer but from heart and blood vessel problems instead, according to new research published in the European Heart Journal today. For some cancers, like breast, prostate, endometrial, and thyroid cancer, around half will die from cardiovascular disease (CVD).
An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia.
› Verified 2 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
Anti-osteoporotic medication is not an effective means for preventing hip fractures among the elderly, concludes a study recently published in the BMJ. According to Professor Teppo Järvinen from the University of Helsinki, who heads the research group, the prevalent assumption that brittle bones cause hip fractures is fundamentally flawed.
While the HIV prevalence in China remains low, the situation in several provinces affected by drug trafficking and illegal blood donations is serious, senior HIV/AIDS control officials said on Saturday, Xinhua/China Daily reports.
Inex Pharmaceuticals announced today that United States Food and Drug Administration (FDA) provided an action letter detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval regulations based on the phase 2 clinical trial data submitted.
More than one in ten cancer patients do not die from their cancer but from heart and blood vessel problems instead, according to new research published in the European Heart Journal today. For some cancers, like breast, prostate, endometrial, and thyroid cancer, around half will die from cardiovascular disease (CVD).
An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brijen L Joshi, MD 9910 Franklin Square Dr Ste 2110, Baltimore, MD 21236-4902 Ph: (410) 933-6423 | Dr Brijen L Joshi, MD 1800 Orleans St, The Johns Hopkins University/the Johns Hopkins Hospital, Baltimore, MD 21287-0010 Ph: (410) 955-5000 |
News Archive
Anti-osteoporotic medication is not an effective means for preventing hip fractures among the elderly, concludes a study recently published in the BMJ. According to Professor Teppo Järvinen from the University of Helsinki, who heads the research group, the prevalent assumption that brittle bones cause hip fractures is fundamentally flawed.
While the HIV prevalence in China remains low, the situation in several provinces affected by drug trafficking and illegal blood donations is serious, senior HIV/AIDS control officials said on Saturday, Xinhua/China Daily reports.
Inex Pharmaceuticals announced today that United States Food and Drug Administration (FDA) provided an action letter detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval regulations based on the phase 2 clinical trial data submitted.
More than one in ten cancer patients do not die from their cancer but from heart and blood vessel problems instead, according to new research published in the European Heart Journal today. For some cancers, like breast, prostate, endometrial, and thyroid cancer, around half will die from cardiovascular disease (CVD).
An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia.
› Verified 2 days ago
Kathryn Rosenblatt, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1800 Orleans St, Baltimore, MD 21287 Phone: 410-955-7461 Fax: 410-614-7903 | |
Dr. Tiffani Danielle Pittman, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5601 Loch Raven Blvd, Baltimore, MD 21239 Phone: 443-444-4863 Fax: 443-444-4997 | |
Aaron Sachs, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 22 S Greene St # S11c, University Of Maryland Department Of Anesthesia, Baltimore, MD 21201 Phone: 410-328-1239 | |
Dr. Mohamed Ehab Ramadan Mohamed Ramadan, MBBCH, MSC, PHD Anesthesiology Medicare: Medicare Enrolled Practice Location: 600 North Wolfe Street, Nelson 2-131, Baltimore, MD 21287 Phone: 410-955-1818 | |
Lynette Mark, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-6353 | |
Charles Lin, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 900 Canton Ave, Baltimore, MD 21229 Phone: 410-368-3045 Fax: 410-951-4009 | |
Dr. Jasjit B Atwal, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 110 S Paca St, Suite 300 6th Fl, Baltimore, MD 21201 Phone: 410-328-6720 Fax: 410-328-1674 |